Mon, Mar 2, 2015, 10:27 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

  • dojothegreat33 dojothegreat33 Jan 7, 2014 9:51 AM Flag

    OT - STEM

    Co will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC human neural stem cells, at the 2014 Alliance for Regenerative Medicine State of the Industry Briefing. Dr. Salinas will discuss the Company's plans for completing ongoing safety studies in spinal cord injury and age related macular degeneration in the first and second quarters of 2014 respectively, as well as the planned initiation of controlled Phase II efficacy studies in both indications in 2014.
    The new trials are being designed as definitive Proof of Concept studies with hard clinical outcomes, which should enable the Company to initiate pivotal Phase III studies, assuming that the results are positive. Dr. Salinas is scheduled to speak on January 13th, from 8:00 to 10:00 a.m., at the conference, which is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACTC
6.97+0.17(+2.50%)Nov 13 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.